dc.contributor.author | Perez-Lopez, R | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Padhani, AR | |
dc.contributor.author | Oyen, WJG | |
dc.contributor.author | Fanti, S | |
dc.contributor.author | Vargas, HA | |
dc.contributor.author | Omlin, A | |
dc.contributor.author | Morris, MJ | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Koh, D-M | |
dc.date.accessioned | 2019-07-22T14:59:24Z | |
dc.date.issued | 2019-08-01 | |
dc.identifier.citation | Radiology, 2019, 292 (2), pp. 273 - 286 | |
dc.identifier.issn | 0033-8419 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3303 | |
dc.identifier.eissn | 1527-1315 | |
dc.identifier.doi | 10.1148/radiol.2019181931 | |
dc.description.abstract | The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, more precise imaging may help physicians deliver better care. More accurate local staging and earlier detection of metastatic disease, accurate identification of oligometastatic disease, and optimal assessment of treatment response are areas where modern imaging is rapidly evolving and expanding. Next-generation imaging modalities, including whole-body MRI and molecular imaging with combined PET and CT and combined PET and MRI using novel radiopharmaceuticals, create new opportunities for imaging to support and refine management pathways in patients with advanced prostate cancer. This article demonstrates the potential and challenges of applying next-generation imaging to deliver the clinical promise of treatment breakthroughs. | |
dc.format | Print-Electronic | |
dc.format.extent | 273 - 286 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | RADIOLOGICAL SOC NORTH AMERICA (RSNA) | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Prostate | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Positron-Emission Tomography | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Neoplasm Staging | |
dc.subject | Follow-Up Studies | |
dc.subject | Male | |
dc.subject | Multimodal Imaging | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.title | Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1148/radiol.2019181931 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Radiology | |
pubs.issue | 2 | |
pubs.notes | 6 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 292 | |
pubs.embargo.terms | 6 months | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Translational Molecular Imaging | |
dc.contributor.icrauthor | De Bono, Johann | |